LIVE INVESTOR WEBINAR
How Cizzle Bio Is Transforming Cancer Diagnostics
In this live investor session, the leadership team at Cizzle Bio will explore how their patented blood test platform, centered around the CIZ1B biomarker, is designed to detect lung cancer in its earliest stages. When it’s most treatable, and most cost-effective to manage.
Tuesday, July 15th at 1:30PM PST
Cizzle was born from a desperate need for faster, earlier detection.
Lung cancer remains the leading cause of cancer-related death worldwide, not because we lack treatments, but because most cases are discovered too late. Cizzle has developed a blood test to identify the presence of CIZ1B, an early indicator of lung cancer.
With deep IP protection and a target market valued at over $100 billion, Cizzle Bio is positioned at the intersection of public health impact and scalable commercial potential.
This is an opportunity to hear directly from the founders and learn why now is a key moment for early-stage investors to get involved.
©2025 Cizzle Bio. All rights reserved.
DISCLAIMER: Equity crowdfunding investments in private placements, and start-up investments in particular, are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups. Companies seeking startup investment through equity crowdfunding tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Further, investors may receive illiquid and/or restricted stock that may be subject to holding period requirements and/or liquidity concerns.